BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 24996233)

  • 21. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
    Quinlan DJ; Eriksson BI
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview of the new oral anticoagulants: opportunities and challenges.
    Yeh CH; Hogg K; Weitz JI
    Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New oral anticoagulants--a review.
    Ghanima W; Atar D; Sandset PM
    Tidsskr Nor Laegeforen; 2013 Oct; 133(18):1940-5. PubMed ID: 24084970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
    Khemasuwan D; Suramaethakul N
    Clin Appl Thromb Hemost; 2012 Sep; 18(5):476-86. PubMed ID: 22387584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
    Amin A; Jing Y; Trocio J; Lin J; Lingohr-Smith M; Graham J
    J Med Econ; 2014 Nov; 17(11):763-70. PubMed ID: 25078794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New anticoagulants: dabigatran, rivaroxaban and apixaban].
    Vargas Ruiz AG; Ramírez López AN; Medina Viramontes ME
    Gac Med Mex; 2012; 148(3):257-64. PubMed ID: 22820359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The new oral anticoagulants in atrial fibrillation: once daily or twice daily?
    Renda G; De Caterina R
    Vascul Pharmacol; 2013; 59(3-4):53-62. PubMed ID: 23872195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
    Contractor T; Levin V; Martinez MW; Marchlinski FE
    Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.
    Steffel J; Braunwald E
    Eur Heart J; 2011 Aug; 32(16):1968-76, 1976a. PubMed ID: 21421599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implications of new anticoagulants in primary practice.
    Perez A; Eraso LH; Merli GJ
    Int J Clin Pract; 2013 Feb; 67(2):139-56. PubMed ID: 23305476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
    Amin A; Stokes M; Makenbaeva D; Wiederkehr D; Wu N; Lawrence JH
    J Med Econ; 2014 Nov; 17(11):771-81. PubMed ID: 25133458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticoagulation: a GP primer on the new oral anticoagulants.
    Brieger D
    Aust Fam Physician; 2014 May; 43(5):254-9. PubMed ID: 24791763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
    Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP; Halperin JL
    Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New oral anticoagulants in practice: pharmacological and practical considerations.
    Wang Y; Bajorek B
    Am J Cardiovasc Drugs; 2014 Jun; 14(3):175-89. PubMed ID: 24452600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Venous thromboembolism management: where do novel anticoagulants fit?
    Spyropoulos AC; Turpie AG
    Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
    Baker WL; Chamberlin KW
    Clin Pharmacol Ther; 2014 Jul; 96(1):17-9. PubMed ID: 24942397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.